Fenwick Represents Veracyte in its Pending Acquisition of C2i Genomics

Fenwick is representing Veracyte Inc. (NASDAQ: VCYT), a global diagnostics company, in its pending acquisition of C2i Genomics, a minimal residual disease (MRD) detection company.

Through the acquisition of C2i Genomics, Veracyte will be positioned to serve physicians and their patients further along the cancer care continuum, in combination with its portfolio of diagnostic and prognostic tests. More information can be obtained from the news announcement.

The Fenwick transaction team includes corporate partners Doug Cogen, Ran Ben-Tzur and Einat Meisel, counsel Chelsea Anderson and associates Rob O’Conner, Zoe Zhang, Brandon Ho and David Heath; technology transactions partner Jake Handy, associates Pinar Bailey and Ju Yun (Julie) Son and advisor Sandra Weustink; executive compensation and employee benefits partner Liz Gartland and associate Elizabeth Fu; and tax partner Adam Halpern and associate Einav Axler.